EUCTR2020-004289-20-DK进行中（未招募）1 期
A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 434
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Has histologically or cytologically confirmed diagnosis of unresectable and metastatic colorectal adenocarcinoma (Stage IV A, B and C as defined by AJCC 8th edition).
- •2. Has been previously treated for their disease and progressed on or after or could not tolerate standard treatment, which must include ALL of the following agents if approved and locally available in the country where the participant is randomized:
- •a. Fluoropyrimidine, irinotecan and oxaliplatin
- •b. With or without an anti-VEGF monoclonal antibody (bevacizumab)
- •c. With anti-EGFR mAbs (cetuximab or panitumumab) for RAS (KRAS/NRAS) WT participants
- •d. BRAF inhibitor (in combination with cetuximab +/- binimetinib) for BRAF V600E mutated mCRC
- •3. Has measurable disease per RECIST 1.1 assessed by the investigator.
- •4. Has provided to a designated central laboratory an archival tumor tissue sample or newly obtained core, incisional or excisional biopsy of a tumor lesion which has not been previously irradiated. Formalin-fixed, paraffin embedded tissue blocks are preferable to slides. Newly obtained biopsies are preferable to archived tissue.
- •5. Has an ECOG performance status of 0 to 1 within 3 days prior to randomization.
- •6. Has a life expectancy of at least 3 months, based on the investigator assessment.
- •7. Has the ability to swallow capsules or ingest a suspension orally or by a feeding tube.
- •8. Has adequately controlled BP with or without antihypertensive medications, defined as BP =150/90 mm Hg with no change in antihypertensive medications within 1 week prior to randomization.
- •9. Has adequate organ function. Specimens must be collected within 3 days prior to the start of study intervention.
- •10. Is male or female =18 years of age at the time of providing documented informed consent.
- •11. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of regorafenib or TAS-102 and at least 7 days after the last dose of lenvatinib:
- •-Refrain from donating sperm
- •PLUS either:
- •-Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent
- •-Must agree to use contraception unless confirmed to be azoospermic as detailed below:
- •Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
- •Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •If the contraception requirements in the local label for any of the study drugs is more stringent than the requirements above, the local label requirements should be followed.
- •12. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a WOCBP
- •Is a WOCBP and using a contraceptive method that is highly effective, with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the intervention period and for at least 30 days after the last dose of lenvatinib, 120 days after the last dose of pembrolizumab (whichever is last), and 180 days after the last dose of regorafenib or TAS-102 and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during
排除标准
- •1. Has a tumor that is MSH-H/dMMR per local testing.
- •2. Has presence of gastrointestinal condition, that might affect the absorption of study drug.
- •3. Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment. The participant can receive diuretic drugs as needed per the treating physician, outside of the above-mentioned conditions.
- •4. Has radiographic evidence of encasement or invasion of a major blood vessel invasion, or of intratumoral cavitation.
- •5. Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug.
- •6. Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
- •7. Has a history of arterial thromboembolism within 12 months of start of study drug.
- •8. Has urine protein =1 g/24h.
- •9. Has prolongation of QTcF interval to >480 ms.
- •10. Has LVEF below the institutional (or local laboratory) normal range as determined by MUGA or ECHO.
- •11. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Exceptions include early stage cancers treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
- •12. Has serious nonhealing wound, ulcer or bone fracture.
- •13. Has had major surgery within 3 weeks prior to first dose of study interventions.
- •14. Has received biologic response modifiers within 4 weeks before study entry. Chronic erythropoietin therapy is permitted provided that no dose adjustments were made within 2 months before first dose of study treatment.
- •15. Has preexisting =Grade 3 gastrointestinal or non-gastrointestinal fistula.
- •16. Has received prior treatment with a combination of an anti-PD-1, anti-PD-L1, or anti PDL2 agent with anti-VEGF mAbs or VEGFR inhibitors.
- •17. Has previously received regorafenib or TAS-102.
- •18. Has received prior systemic anti-cancer therapy including investigational agents within 28 days prior to randomization.
- •19. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •20. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines are allowed.
- •21. Has known intolerance to lenvatinib, regorafenib or TAS-102 and/or any of their excipients.
- •22. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days prior to the first dose of study intervention.
- •23. Has known CNS metastases and/or carcinomatous meningitis.
- •24. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients.
- •25. Has an active autoimmune disease that has required systemic treatment in
研究者
相似试验
进行中（未招募）
3 期
A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal Cancer (LEAP-017)unresectable non MSIH/dMMR mCRCJPRN-jRCT2031200453Shimoyama Ryo60
进行中（未招募）
1 期
A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal CancerColorectal CarcinomaMedDRA version: 20.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864EUCTR2020-004289-20-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.434
招募中
3 期
SELECT-400Hepatocellular carcinomaHepatocellular carcinoma, drug therapyJPRN-jRCT1031210092eno Makoto130
已完成
不适用
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)PER-035-02SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
3 期
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)Colorectal NeoplasmsNCT04776148Merck Sharp & Dohme LLC563